Impact of the pandemic and concomitant COVID-19 on the management and outcomes of middle cerebral artery strokes: a nationwide registry-based study.

COVID-19 neurology stroke

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
27 Feb 2024
Historique:
medline: 29 2 2024
pubmed: 29 2 2024
entrez: 28 2 2024
Statut: epublish

Résumé

To investigate the impact of the COVID-19 pandemic as well as concomitant COVID-19 itself on stroke care, focusing on middle cerebral artery (MCA) territory infarctions. Registry-based study. We used the National Inpatient Sample (NIS) database, which covers a wide range of hospitals within the USA. The NIS was queried for patients with MCA strokes between 2016 and 2020. In total, 35 231 patients were included. Outcome measures were postprocedural complications, length of stays (LOSs), in-hospital mortality and non-routine discharge. Propensity score matching using all available baseline variables was performed to reduce confounders when comparing patients with and without concomitant COVID-19. Mechanical thrombectomy (MT) was performed in 48.4%, intravenous thrombolysis (IVT) in 38.2%, and both MT and IVT (MT+IVT) in 13.4% of patients. A gradual increase in the use of MT and an opposite decrease in the use of IVT (p<0.001) was detected during the study period. Overall, 25.0% of all patients were admitted for MCA strokes during the pandemic period (2020), of these 209 (2.4%) were concomitantly diagnosed with COVID-19. Patients with MCA strokes and concomitant COVID-19 were significantly younger (64.9 vs 70.0; p<0.001), had significantly worse NIH Stroke Severity scores, and worse outcomes in terms of LOS (12.3 vs 8.2; p<0.001), in-hospital mortality (26.3% vs 9.8%; p<0.001) and non-routine discharge (84.2% vs 76.9%; p=0.013), as compared with those without COVID-19. After matching, only in-hospital mortality rates remained significantly higher in patients with COVID-19 (26.7% vs 8.5%; p<0.001). Additionally, patients with COVID-19 had higher rates of thromboembolic (12.3% vs 7.6%; p=0.035) and respiratory (11.3% vs 6.6%; p=0.029) complications. Among patients with MCA stroke, those with concomitant COVID-19 were significantly younger and had higher stroke severity scores. They were more likely to experience thromboembolic and respiratory complications and in-hospital mortality compared with matched controls.

Identifiants

pubmed: 38417967
pii: bmjopen-2023-080738
doi: 10.1136/bmjopen-2023-080738
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e080738

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Abdul Karim Ghaith (AK)

Mayo Clinic, Rochester, Minnesota, USA.

Victor Gabriel El-Hajj (VG)

Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Elias Atallah (E)

Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Jorge Rios Zermeno (J)

Mayo Clinic in Florida, Jacksonville, Florida, USA.

Krishnan Ravindran (K)

Mayo Clinic in Florida, Jacksonville, Florida, USA.

Maria Gharios (M)

Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Harry Hoang (H)

Mayo Clinic, Rochester, Minnesota, USA.

Mohamad Bydon (M)

Mayo Clinic, Rochester, Minnesota, USA.

Marcus Ohlsson (M)

Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Adrian Elmi-Terander (A)

Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden adrian.elmi.terander@ki.se.

Rabih G Tawk (RG)

Mayo Clinic in Florida, Jacksonville, Florida, USA.

Pascal Jabbour (P)

Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Classifications MeSH